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Summary
The Hedgehog (Hh) signaling pathway has conserved
roles in development of species ranging from Dro-
sophila to humans. Responses to Hh are mediated
by the transcription factor Cubitus interruptus (Ci;
GLIs 1–3 in mammals), and constitutive activation of
Hh target gene expression has been linked to several
types of human cancer. In Drosophila, the kinesin-
like protein Costal2 (Cos2), which associates directly
with the Hh receptor component Smoothened (Smo),
is essential for suppression of the transcriptional ac-
tivity of Ci in the absence of ligand. Another protein,
Suppressor of Fused (Su(Fu)), exerts a weak negative
influence on Ci activity. Based on analysis of func-
tional and sequence conservation of Cos2 orthologs,
Su(Fu), Smo, and Ci/GLI proteins, we find here that
Drosophila and mammalian Hh signaling mechanisms
have diverged, and that, in mouse cells, major Cos2-
like activities are absent and the inhibition of the Hh
pathway in the absence of ligand critically depends
on Su(Fu).
Introduction
The binding of Hh to its receptor activates a signaling
cascade that ultimately leads to an increased activity
of the Ci/GLI family of transcription factors (Collins and
Cohen, 2005; Lum and Beachy, 2004). Several cytoplas-
mic components of this pathway have been described in
Drosophila, including the serine/threonine kinase Fused
(Fu), the novel protein Su(Fu), and the kinesin-like pro-
tein Cos2 (Sisson et al., 1997; Robbins et al., 1997). Hh
signaling is intact in Drosophila embryos lacking
Su(Fu) function, and such embryos develop into viable
and fertile adults (Preat, 1992). In contrast, Cos2 is a crit-
ical component of the Hh pathway whose loss is embry-
onic lethal due to constitutive activation of the Hh path-
way (Grau and Simpson, 1987; Sisson et al., 1997). Cos2
is required for inhibition of Ci transcriptional activator
activity in the absence of Hh, and it acts by anchoring
full-length Ci to the cytoplasm and by inducing the pro-
teolytic processing of the activator form of Ci to a repres-
sor form (CiR). Cos2 associates directly with Drosophila
Smo (dSmo [Jia et al., 2003; Lum et al., 2003b; Ruel et al.,
2003]), a seven transmembrane protein that, together
with the 12-span transmembrane protein Patched
*Correspondence: jussi.taipale@helsinki.fi(Ptc), is responsible for transducing the Hh signal to
the cytoplasm (Stone et al., 1996; Taipale et al., 2002).
Hh signaling is initiated by binding of Hh to Ptc, result-
ing in loss of Ptc activity and consequent phosphoryla-
tion and posttranscriptional stabilization of dSmo (Al-
cedo et al., 2000; Denef et al., 2000). Phosphorylation
occurs at multiple sites at the C-terminal region of
dSmo (Zhang et al., 2004), and mutation of both PKA
and Casein kinase 1a sites to alanine and glutamate or
aspartate results in inactive and hyperactive dSmo pro-
teins, respectively (Jia et al., 2004; Zhang et al., 2004).
The domain of dSmo that is phosphorylated in response
to Hh is also the region responsible for binding to Cos2
(Jia et al., 2003; Lum et al., 2003b), and the prevailing
model of Hh signaling is that this interaction allows
Cos2 to relay a signal from the receptor to the transcrip-
tion factor (Ci [Lum et al., 2003b]).
In Drosophila, Cos2 and dSmo form a stoichiometric
protein complex. Overexpression of Cos2 inhibits Hh
signaling, and this inhibition can be rescued by overex-
pression of dSmo (Lum et al., 2003b). However, it is not
clear whether these effects are due to Cos2 inhibiting
dSmo activity, or vice versa, as conclusive epistasis
analysis of Cos2 and dSmo mutants has not been per-
formed.
Most components of the Hh pathway have been ini-
tially described in Drosophila, and their mammalian ho-
mologs have been identified later. However, despite
the critical role of Cos2 in Drosophila, mammalian pro-
teins acting equivalently to Cos2 have not been de-
scribed (see, however, Tay et al. [2005]). Because of
the well-established and central role of Cos2 in the Dro-
sophila Hh pathway, we decided to analyze the role of
Cos2-like activity in mammalian Hh signaling. We found
that the mouse Smo (mSmo) C-terminal domain that in
Drosophila is phosphorylated in response to Hh and
binds to Cos2 is not required for mSmo function. Con-
versely, introduction of the Drosophila Smo C-terminal
sequences to mSmo renders mammalian Hh signaling
Cos2 sensitive. We further found that the two orthologs
to Cos2, Kif7 and Kif27, do not affect Shh signaling in
mouse cells, and that, in contrast, RNAi-induced loss
of Su(Fu) expression results in a dramatic increase in
Shh pathway activity. Taken together, these results indi-
cate thatDrosophila and mammalian Hh signaling mech-
anisms have diverged at the level of Smo, Cos2, and
Su(Fu).
Results
Analysis of the Requirement of the mSmo
C-Terminal Domain in Shh Signaling
To test whether mammalian Smo acts through Cos2-like
proteins, we analyzed whether the C-terminal domain
is required for mSmo function, by using a cell line,
s4Smo2/2, derived from fibroblasts from E8.5 mSmo null
embryos (Ma et al., 2002). To assay Hh pathway activity,
we used a GLI-luciferase reporter that is sensitive to
both activator and repressor forms of GLI. This reporter
is induced by GLI2 expression or Shh treatment, and its
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178Figure 1. A Small C-Terminal Cytoplasmic Tail Is Required for mSmo
Activity
(A) mSmo expression rescues the Hh signaling defect in s4Smo2/2
cells. s4Smo2/2 cells were cotransfected with reporters for the Shh
pathway and for transfection efficiency together with control vector
(control), wild-type mSmo (mSmo), or oncogenically activated mSmo
(mSmoA1). Relative luciferase activity (y axis) was measured after
2 days of incubation in the absence (white bars) or presence
(gray bars) of ShhN-conditioned medium. In all panels, error bars in-
dicate one standard deviation (quadruplicate wells). Inset: PCR
analysis of control and s4Smo2/2 cells for the presence of mSmo
exon1.
(B) Analysis of the optimal mSmo expression level in s4Smo2/2 cells.
Fold induction by ShhN and the percentage of the mSmo expres-
sion construct (w/w) of total plasmid are indicated above and below
the bars, respectively.
(C) Definition of the minimal C-terminal domain that is required for
mSmo activity. Two domains corresponding in amino acid sequence
to the segments in Drosophila Smo that bind to Cos2 are indicated
on the left. The first of these (small, red box) is in a region conserved
between Drosophila and mouse, whereas the second domain (large,
red box) is located in a region that is largely divergent between
mouse and Drosophila. Note that constructs lacking these domains
can rescue the loss of mSmo. Inset: Western blot analysis of theShh-induced activity is inhibited by GLI3 repressor ex-
pression or by an inducer of endogenous GLI3 repressor
formation, forskolin (Taipale et al., 2000, 2002). Using
this reporter, we found that, in the absence of cotrans-
fected mSmo, the s4Smo2/2 cells were completely re-
fractory to Hh (Figure 1A). Transfection of DNA contain-
ing as little as 1% (w/w) of mSmo expression construct
to s4Smo2/2 cells completely rescued the ability of the
cells to respond to ShhN (N-terminal signaling domain
of Sonic hedgehog, a mouse homolog of Drosophila
Hh). Expression of oncogenically activated mSmo re-
sulted in constitutive activation of the pathway, even in
the absence of ShhN. At low mSmo concentration,
a >15-fold induction of pathway activity by ShhN was
observed, and increasing the expression level of
mSmo resulted in increased basal activity, but did not
further increase the ShhN-induced level of pathway ac-
tivity (Figure 1B).
We next tested whether domains in mSmo analogous
to the dSmo Cos2 binding domains are required for
mSmo function. In Drosophila Smo, there are two do-
mains that are critical for Cos2 binding, located between
amino acids 652–686 (Lum et al., 2003b) and 730–1035
(Jia et al., 2003). dSmo lacking both of these domains
has no activity, and it fails to bind to Cos2 (Lum et al.,
2003b; Nakano et al., 2004). In contrast, a corresponding
mSmo construct (mSmo637DC) had strong, but partial,
activity (Figure 1C). Increasing the expression level in-
creased the maximal activity, suggesting that the de-
leted domains were not critical for activity, but that
they allowed more efficient mSmo function (Figure
S1A; see the Supplemental Data available with this arti-
cle online). Because maximal activity was not observed
when using the highest dose of mSmo637DC construct
tested, we specifically deleted the amino acids 638–656
from full-length mSmo. This construct had strong activ-
ity (>80%), indicating that this segment is not required
for Shh pathway activation by mSmo.
mSmo constructs with longer C-terminal tails
(mSmo685DC and mSmo714DC) had activity similar to
wild-type mSmo (Figure 1C; Figure S1A). In contrast, in
Drosophila, a construct corresponding to mSmo714DC
(dSmo724DC) has very weak activity and fails to rescue
dSmo loss, and only a construct having both Cos2 bind-
ing domains rescues dSmo activity (Nakano et al., 2004).
These results indicate that the two regions that are crit-
ical for Cos2 binding and Smo activity in Drosophila are
not required for induction of GLI activity by mouse Smo.
Alanine Scan Mutagenesis of Conserved
Cytoplasmic Residues in mSmo
To further define residues in mSmo required for down-
stream signaling, we performed an alanine scan of the
cytoplasmic side of the minimal active domain of
mSmo (Figures 2A and 2B; alanines mutated to glycine).
This analysis identified eight residues whose mutation
resulted in significant loss of mSmo activity. Two of
these residues were in the third intracellular loop, and
six residues were in the C-terminal cytoplasmic tail
(Figure 2A). All of the inactivating mutants were normally
constructs expressed in COS1 cells. The fast- and slow-migrating
bands correspond to the differentially glycosylated ER and post-
ER forms of mSmo, respectively.
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179Figure 2. Identification of Critical Residues in
mSmo that Are Required for Downstream
Signaling
(A) Schematic representation of mSmo struc-
ture. Circled residues have been mutated to
alanine (alanines to glycine), and their activi-
ties are represented by a color code: red, light
red, light green, and green indicate less than
10%, 25%, 50%, and more than 50% activity,
respectively. Absolute conservation and se-
quence similarity are indicated by bold and
italic typeface, respectively. Arrowheads indi-
cate deletion constructs described in Figure 1
(mouse) and in Lum et al. (2003b) forDrosoph-
ila. The longer Drosophila Smo C-terminal tail
is indicated by a thin, blue line (not in scale).
(B) Activity of point mutant mSmo proteins.
s4Smo2/2 cells were transfected with re-
porters and the different point mutant con-
structs. Relative luciferase activity was deter-
mined after 2 days of incubation in the
presence of ShhN-conditioned medium. The
activity of wild-type mSmo is normalized to
1; red, light-red, and light-green horizontal
lines indicate 10%, 25%, and 50% activity,
respectively.
(C) Normal expression and exit from the ER of
inactivated mutant forms of mSmo. The inac-
tivated mutant forms of mSmo were ex-
pressed in COS1 cells, and the lysates were
analyzed for protein expression by Western
blotting. Note that the band corresponding
to the post-ER form of mSmo is present in
wild-type mSmo and in all inactivating forms
of mSmo, but not in the oncogenically acti-
vated mSmoA1 protein, which fails to exit
the ER (Chen et al., 2002a).
(D) Normal folding of the I573A-inactivated
mSmo mutant. COS1 cells expressing wild-
type, I573A, and oncogenically activated
mSmo (mSmoA1) were incubated with a fluo-
rescent small molecule that binds to mSmo
(GF-cyclopamine), followed by flow cytome-
try analysis. Note that wild-type mSmo and in-
active mSmoI573A bind to GF-cyclopamine,
whereas mSmoA1 does not.
(E) Analysis of mSmo protein expression
levels in stable lines of mSmo null cells ex-
pressing myc-tagged mSmo indicate that
mSmo protein is not stabilized by the addition
of ShhN.expressed in mammalian cells, matured to the post-ER
slow-migrating form (Figure 2C), and bound wild-type
levels of the fluorescent Smo antagonist GF-cyclop-
amine (Figure 2D and data not shown), indicating that
they were properly folded. Only one of these mutants,
I573A, has been described previously. The correspond-
ing mutation in Drosophila, I586A, results in an unstable
dSmo protein (Lum et al., 2003b) (Figure S1C). This in-
stability was interpreted to be the primary cause of the
lack of activity of I586A mutant dSmo, but since in Dro-
sophila activity of dSmo is coupled to stabilization (Al-
cedo et al., 2000), it is more likely in the light of our obser-
vations that the I586A mutant protein is degraded
because it fails to become activated. In mammals, all
of the inactivating mutant forms of mSmo, including
I573A, are expressed normally, probably because acti-
vation of the Hh pathway is not coupled to mSmo stabi-
lization in mammals (Figure 2E). In mouse cells, mSmo
is not stabilized after the addition of ShhN to fully Shh-responsive stable lines of Smo2/2 cells expressing
triple-myc-tagged mSmo (Figure 2E and data not
shown), or after the addition of ShhNp to NIH-3T3 cells
transiently transfected to express low levels of Renilla
luciferase-tagged mSmo (data not shown). Since dSmo
stabilization in Drosophila requires Cos2 function (Lum
et al., 2003b), lack of mSmo stabilization in mammals
is also consistent with the lack of requirement for Cos2
binding domains in mSmo function. In aggregate, these
results indicate that specific sequence elements within
the mSmo cytoplasmic tail are critical for mSmo func-
tion, but that these domains do not include, and are
N-terminal to, the regions corresponding to the domains
that are critical in Drosophila Smo for Cos2 binding.
Comparison of the Activity of Mouse
and Drosophila Smo C-Terminal Domains
In Drosophila, overexpression of myr-mSmoC, a mSmo
C-terminal cytoplasmic domain that is anchored to the
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(A) Expression of the membrane-tethered mouse Smo C-terminal cytoplasmic domain (myr-mSmoC) does not activate the mammalian Hh path-
way in NIH-3T3 cells expressing endogenous Smo. The expression of myr-mSmoC in the plasma membrane was confirmed by confocal fluo-
rescence microscopy (data not shown).
(B) Analysis of myr-mSmoC-expressing transgenic mouse embryos. Note the wild-type digit pattern. Inset: Tail DNA PCR genotyping and West-
ern blotting analysis used to identify transgenic embryos. The fast-migrating DNA band is from the transgenic construct, whereas the slow-
migrating band is from endogenous Smo and contains an intron (this intron-containing band is competed out in the transgenic sample).
(C) Mouse Shh signaling is insensitive to Drosophila Cos2, but it can be made Cos2 sensitive by replacing mSmo C-terminal sequences with
dSmo C-terminal sequences. Note that mSmo with C-terminal domains from dSmo with wild-type (Smo/w), inactivating (Smo/i), and activating
(Smo/a) mutations have similar activity (at 2% w/w DNA), which can, in all cases, be completely blocked by coexpression of Drosophila Cos2
(+Cos2, 25% w/w pCMV-Cos2 DNA).
(D) Drosophila Cos2 strongly represses Ci activity in S2 cells, but it has no effect on GLI2 activity. S2 cells were transfected with a Drosophila Hh
pathway reporter, a Renilla luciferase transfection control reporter, and GLI2 (boxes) or Ci (diamonds) expression constructs together with
increasing concentrations of the Drosophila Cos2 expression construct. Note that Cos2 can completely inhibit Ci activity, and that even at
the Cos2:Ci vector ratio of 1:25, only 50% activity of the Hh pathway is observed.
Error bars in (A), (C), and (D) indicate one standard deviation (quadruplicate wells).internal leaflet of the plasma membrane by a myristoyl
moiety, inhibits processing of Ci to a repressor form by
inducing a loss of Cos2 activity (Hooper, 2003; Jia
et al., 2003). In contrast, the expression of myr-mSmoC
did not induce the Hh pathway in NIH-3T3 (Figure 3A) or
s4Smo2/2 cells (Figure S1B). It is possible that subtle in-
duction of the pathway, such as that induced by a loss of
processing of GLI3 to a repressor form, would not be de-
tected in our cultured cell assay. Therefore, we made
transgenic embryos expressing myr-mSmoC, and we
analyzed their phenotype at E16. A relatively minor in-
duction of the Hh pathway would be readily visible as
polydactyly at this stage (Hui and Joyner, 1993). How-
ever, the mouse embryos expressing myr-mSmoC dis-
played a wild-type limb pattern (Figure 3B). These re-
sults suggest that, in contrast to the Drosophila Smo C
terminus, the mouse Smo C-terminal domain does not
bind to and inactivate proteins, such as Cos2, which
are required for suppression of Shh pathway activity in
the absence of ligand. In contrast, the requirement of
a segment of the C terminus for mSmo activity and the
absence of the effect of this segment when expressed
alone suggest that the activity of mSmo requires an in-
teraction between the C-terminal cytoplasmic region
and the seven-transmembrane domain.To more directly test whether the divergence between
mouse and Drosophila Smo C-terminal domain function
is due to Cos2 binding, we tested the ability of the dSmo
C-terminal domain to function in the context of mSmo by
replacing most of the mSmo C-terminal region with the
dSmo C-terminal sequences (Figure 3C). The substitu-
tion did not interfere with the activity of mSmo, as this
construct could rescue Shh signaling in s4Smo2/2 cells
(Figure 3C). Inclusion of previously described mutations
(Zhang et al., 2004) of multiple phosphorylation sites that
render dSmo inactive or hyperactive did not change the
activity of this construct (Smo/i and Smo/a in Figure 3C),
suggesting that signaling events downstream from Smo
have diverged between Drosophila and mice.
We next tested the effect of expression of Drosophila
Cos2 in mouse s4Smo2/2 cells coexpressing the different
mouse/Drosophila hybrid Smo proteins. Expression of
Drosophila Cos2 in the s4Smo2/2 cells had no effect on
Shh pathway activity in the presence or absence of a co-
transfected full-length mSmo construct (Figure 3C). In
contrast, expression of Drosophila Cos2 completely
abolished activity of mSmo with the dSmo C-terminal
tail, regardless of whether the Drosophila sequences
were wild-type (Smo/w) or contained inactivating
(Smo/i) or activating (Smo/a) mutations (Figure 3C).
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181Figure 4. Divergence of the Function of the Mammalian and Drosophila Cos2 Orthologs
(A) Top: GST pull-down Western blotting analysis from S2 cell lysates indicates that theDrosophila Smo cytoplasmic tail incorporating the I586A
mutation retains its Cos2 binding activity. Bottom: Coomassie blue-stained GST fusion proteins (fusion proteins).
(B) A schematic representation of Kif27 and Kif7 structures.
(C) A multiple-tissue Northern blot indicates that Kif27 is weakly expressed in adult mouse heart (He), brain (Br), spleen (Sp), lung (Lu), liver (Li),
skeletal muscle (Sk), and kidney (Ki), and in embryos at E11, E15, and E17. Another Cos2-related kinesin, Kif7, is only expressed in the adult
mouse kidney.
(D and E) The closest homologs of Cos2 in the mouse, Kif27 and Kif7, have no effect on Shh signaling. NIH-3T3 cells were transfected with re-
porters and the constructs indicated, and cells were incubated for 2 days in the absence (white bars) or presence (gray bars) of ShhN-conditioned
medium. Note that Kif proteins (45% of DNA w/w) have no effect on Shh signaling in the absence or presence of GLI2 (5%) expression. In all
panels, error bars indicate one standard deviation (quadruplicate wells).
(F) Cargo domains of Kif3, Kif7, and Kif27 do not associate with mSmo. COS1 cells were transfected with the constructs indicated, and, after 2
days, lysates of the cells were subjected to immunoprecipitation with polyclonal antibodies to the myc epitope, followed by Western blotting with
monoclonal antibodies against the V5 epitope. Top panel: input (1.5% of immunoprecipitated material); middle panel: V5 Western blot (50% of
precipitate); bottom panel, myc Western blot (0.5% of precipitate).These results indicate that Drosophila Cos2 is ex-
pressed in a functional form in mouse cells; yet, it has
no effect on Shh signaling unless critical Drosophila se-
quences are incorporated into mSmo. Consistently, with
these observations, Cos2 did not affect transcriptional
activity of mammalian GLI2 in Drosophila S2 cells, de-
spite the known Hh responsiveness of GLI2 in Drosoph-
ila in vivo (Aza-Blanc et al., 2000) and strong inhibition of
Ci activity in the same assay (Figure 3D). Furthermore,
introduction of a mutation that inactivates both mouse
and Drosophila Smo into the dSmo C-terminal domain
(dSmoC-I586A) did not affect its ability to bind to Dro-
sophila Cos2, suggesting that the conserved aspect of
the Smo mechanism that is inactivated by the mutation
of this residue does not involve regulation of Cos2 bind-
ing (Figure 4A).
Analysis of the Activity of Mammalian
Cos2 Orthologs
To further analyze the role of Cos2-like activity in mam-
malian Hh signal transduction, we isolated cDNA for the
closest homolog to Cos2 in the mouse genome, the ki-
nesin-like protein Kif27 (Figure 4B; Figure S2). BLAST
analysis with either full-length sequence or motor or
stalk domains of Drosophila Cos2 identifies Kif27 as its
closest mouse homolog. Conversely, the most closely
related sequence to mouse Kif27 in the Drosophila ge-
nome is Cos2. Kif27 is a 158.9 kDa protein with 38.1%
amino acid similarity to Drosophila Cos2. It is expressed
strongly in mouse testis (data not shown), and weakly in
other tissues, and in embryos at E11–E17 (Figure 4C). It
migrates as a single band ofw170 kDa in SDS-PAGE un-der reducing conditions. Kif7 has slightly lower se-
quence similarity to Cos2 (37.4%), and from the embry-
onic and adult tissues we examined, it is only expressed
in the adult mouse kidney (Figure 4C), and in testis as an
alternatively spliced short form (data not shown).
The Drosophila and A. gambiae Cos2 proteins have
significantly diverged from members of the kinesin fam-
ily, and they lack a discernible N2-switch1 motif and con-
tain four and five mutations, respectively, in residues that
are absolutely conserved in the other nucleotide binding
and switch motifs in all other kinesin motor domains
(Block, 1998) (Figure S2). In contrast, the vertebrate
Kif7 and Kif27 proteins have all of the sequence charac-
teristics of microtubule-dependent molecular motors,
indicating that they have not been subject to similar se-
lective pressure as the insect Cos2 proteins. Consis-
tently, expression of Kif27 (Figure 4D) or Kif7 (Figure
4E) had little effect on Hh signaling in NIH-3T3 cells, or
in s4Smo2/2 cells rescued with mSmo with mouse or
the Drosophila C-terminal tail (Figure S3B). In addition,
Kif7 or Kif27 had no effect on transcriptional activity of
coexpressed GLIs 1–3 (Figures 4D and 4E; Figure S3A),
in marked contrast to the case in Drosophila, in which
Cos2 inhibits the response of cl-8 cells to Hh, and coex-
pression of Cos2 with Ci results in strong suppression of
Ci transcriptional activity (Figure 3D and Lum et al.
[2003b]).
Next, we studied the biochemical interactions be-
tween the Kif proteins and mSmo by coimmunoprecipi-
tation analyses.DrosophilaCos2 binds to dSmo through
its cargo domain (Jia et al., 2003). However, mammalian
Kif3a, Kif7, or Kif27 cargo domains did not associate
Developmental Cell
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(A) Su(Fu), but not Kif7 or Kif27, prevents nuclear localization of GLI2-GFP and GLI3-GFP. Hh-responsive NIH-3T3 cells were transfected with the
constructs indicated, and GFP was observed with a fluorescence microscope after 2 days. Kif7-FLAG, Kif27-V5, and Su(Fu)-V5 were detected by
immunostaining with antibodies to the FLAG and V5 epitope tags. Representative images of more than 100 cells analyzed are shown. Note that
GLI3 is found in the cytoplasm and more predominantly in the nucleus, whereas GLI2 is almost exclusively nuclear, and that neither Kif7 nor Kif27
expression affects their distribution.
(B) shRNA-mediated ‘‘knock down’’ of Gli2 and mSmo inhibits the Hh pathway in NIH-3T3 cells. NIH-3T3 cells, together with shRNA expression
constructs against Gli2, mSmo, and a control protein, neogenin, were transfected with reporters and incubated in the absence (white bars) or
presence (gray bars) of ShhN-conditioned medium. RNAi efficiencies of the different mSmo shRNA constructs are indicated above the bars. In-
set: Schematic structure of the mSmo-Renilla luciferase fusion transcript used to validate the efficiency of the RNA interference.
(C and D) RNA interference against Su(Fu) induces the Hh pathway in the absence of ligand. Compare to the activation observed when Ptc shRNA
is used. Note that Kif7 and Kif27 shRNAs separately (C) or in combination (D) do not activate the Shh pathway. Error bars indicate one standard
deviation (n = 4). RNAi efficiency is also indicated above the bars, and it was measured similarly to the process described in (A), except that Kif7,
Kif27, Su(Fu), and Ptc-Renilla luciferase fusion constructs were used.
(E) A sensitized assay reveals complete activation of the Hh pathway by shRNAs against Su(Fu). The assay was performed similarly to the one
described in (A), except all transfections included a 0.5% (w/w) GLI2 expression construct (n = 8, error bars indicate one standard error). Reporter
activity in the absence of ShhN was normalized to reporter activity in the presence of ShhN for each construct. Note that validated shRNAs
against Kif7 or Kif27 have no effect on Hh pathway activity.with immunoprecipitated full-length mSmo (Figure 4F).
Interestingly, Kif3a, which has been reported to posi-
tively regulate Hh signaling (Huangfu and Anderson,
2005), bound to the control protein, Dishevelled, which
acts on the Wnt pathway. Drosophila Cos2 also binds
to Ci and prevents Ci nuclear localization. However, ex-
pression of either mouse or zebrafish Kif7 or Kif27 did
not affect subcellular localization of GLI2- or GLI3-GFP
fusion proteins (Figure 5A; Figure S4). Similarly, expres-
sion of Kif3a or Kif23, the human homolog of Pavarotti,
a kinesin that, inDrosophila, affects Hh signaling (Collins
and Cohen, 2005), had no effect on GLI2 or GLI3 locali-
zation, GLI1 transcriptional activity, or Shh pathway ac-
tivity (Figure S4 and data not shown). In addition, none of
the Kif proteins increased the processing of GLI3 to a re-
pressor form in COS1 cells (data not shown). In contrast,
as shown earlier for GLI1 (Kogerman et al., 1999), coex-
pression of Su(Fu) dramatically inhibited nuclear locali-
zation of both GLI2- and GLI3-GFP proteins (Figure 5A).RNAi Analysis of Mammalian Cos2 Homologs
and Suppressor of Fused
Based on these results, we reasoned that it is possible
that Cos2-like activity is not required in mammalian cells
if endogenous Su(Fu) activity would suffice to inhibit GLI
transcriptional activity. Gain of function of Su(Fu) very
potently inhibits nuclear localization of GLI2 and GLI3
(above, and Kogerman et al. [1999]), but loss-of-function
studies of Su(Fu) have not been performed in mammals.
We decided to knock down Su(Fu) and the Cos2 homo-
logs by using RNA interference (RNAi) in NIH-3T3 cells.
To test the feasibility of using RNA interference in NIH-
3T3 cells, we designed five short hairpin RNA (shRNA)
constructs (see Supplemental Experimental Procedures
available with this article online) against two positive
regulators of the Hh pathway, Gli2 and mSmo, and a con-
trol protein, Neogenin. All five shRNA constructs de-
signed against Gli2 and mSmo significantly suppressed
pathway activity relative to control (Figure 5B). We
Su(Fu) and Cos2 in Mammalian Hh Signaling
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by analyzing the ability of the mSmo shRNAs to sup-
press the expression of a mSmo-Renilla luciferase fu-
sion protein. The shRNAs displayed 55%–83% potency
in this assay (Figure 5B), and a strong positive correla-
tion was observed between the potency of the shRNAs
and their activity in suppression of Shh signaling. We
then prepared five shRNA constructs against the possi-
ble or known negative regulators of the Hh pathway,
Su(Fu), Kif7, Kif27, and Ptc. All shRNAs against Ptc sig-
nificantly elevated pathway activity in the absence of
Shh. Those Su(Fu) shRNAs that displayed high potency
in RNAi also significantly induced the pathway, whereas
targeting Kif7 or Kif27 alone (Figure 5C) or in combina-
tion (Figure 5D) had no effect. Also, shRNAs targeting
Kif3a or Kif23 had no effect, and SuFu shRNAs also in-
duced the Hh pathway in s4Smo2/2 cells, indicating that
SuFu acts downstream of mSmo (data not shown).
The partial effect of Su(Fu) shRNAs could be due to
the fact that Su(Fu) is in substantial excess of GLI2.
Mammalian cells contain high levels of Su(Fu), and
only a small fraction of the Su(Fu) becomes phosphory-
lated upon Hh stimulation (Paces-Fessy et al., 2004).
RNAi does not directly affect protein levels, but it results
in a decrease of mRNA expression. During the average
of two cell divisions allowed by our experimental proto-
col, even a 100% effective RNAi would result in only
a 75% decrease in the expression level of a completely
stable protein. To overcome this intrinsic limitation, we
sensitized the RNAi assay by expressing a level of
GLI2 construct (0.5% w/w DNA) that by itself resulted
in approximately half-maximal pathway activity in the
absence of ligand. Under these conditions, the assay
is in the linear range and is thus not subject to threshold
effects, being optimally sensitive to changes in the con-
centration of negative regulators of GLI2. Because of
cell division, even small decreases in mRNA levels in-
duced by shRNAs will affect expression of even a com-
pletely stable endogenous protein. A change in expres-
sion of a protein that negatively regulates GLI2 should
then result in a change in reporter activity. Even under
these conditions, shRNA-mediated inhibition of Kif7 or
Kif27 had no effect on Hh pathway activity. In contrast,
shRNA knockdown of Su(Fu) resulted in complete acti-
vation of the Shh pathway (Figure 5E). These results in-
dicate that endogenous Kif7 or Kif27 are not involved in
inhibiting GLI2 activity, and that endogenous Su(Fu) is
a critical regulator of GLI2 activity.
Discussion
Evidence for Divergence of Mammalian
and Drosophila Hh Signaling Mechanisms
at the Level of Costal2 and Su(Fu)
Taken together, the evidence we present indicates that
a significant divergence in the mechanism of Shh signal
transduction has occurred between vertebrates and in-
vertebrates at the level of Smo, Cos2, and Su(Fu). Our re-
sults indicate that major Cos2-like activities are absent
in mouse cells based on four observations: (1) domains
in Smo that are required in Drosophila to bind to Cos2
are not required for mSmo function; (2) mouse Shh sig-
naling is insensitive to expression of Drosophila Cos2,
but can be rendered Cos2 sensitive by replacing themSmo C-terminal domain with the dSmo C-terminal do-
main; (3) expression of the Smo C-terminal domain that,
in Drosophila, inactivates Cos2 has no effect in the
mouse in vivo or in vitro; (4) overexpression or RNAi-
mediated suppression of mouse Cos2 homologs has no
effect on Hh signaling, even under sensitized conditions.
These results are also consistent with divergence of the
sequence of domains involved in Cos2 binding in Ci/GLI
proteins and Smo between insects and mammals
(Figure S2).
Although the RNAi experiments targeting Kif7 and
Kif27 individually were performed under conditions in
which negative regulators of GLI2 were limiting (Figure
5E), they could be argued to be consistent with a model
in which multiple kinesins with Cos2-like activity would
act in a redundant fashion in mammals. By loss-of-
function studies of individual kinesins in cell culture or
in mice it would be difficult to obtain conclusive evi-
dence against such a model due to the potential redun-
dancy of multiple members of the kinesin family. How-
ever, several other in vitro and in vivo experiments that
we present directly contradict such a model. These in-
clude RNAi analyses targeting multiple Kif proteins
(Figure 5D), the analysis of loss of function of mSmo do-
mains (Figures 1C and 3C), and the lack of effect of over-
expression of myr-mSmoC (Figures 3A and 3B) and the
Cos2 orthologs Kif7 and Kif27 (Figures 4D and 4E;
Figure S4). In addition, we could not find a kinesin with
Cos2-like activity by extending the analyses to several
other kinesins, which show homology to Cos2 but
have different fly orthologs (Figures S5 and S6).
We find here that, in contrast to the case in Drosoph-
ila, Su(Fu) has a critical role in suppression of the mam-
malian Hh pathway in the absence of ligand, and loss of
Su(Fu) function results in dramatic induction of GLI tran-
scriptional activity (Figure 6). Our results are also consis-
tent with the studies of Cooper et al. (2005) and Sva¨rd
et al. (2006) (in this issue of Developmental Cell), who
show that loss of Su(Fu) in mouse embryos results in
complete activation of the Hh pathway, in a fashion sim-
ilar to the loss of Ptc. These results are particularly sur-
prising in light of the central role of Cos2 and a minor role
of Su(Fu) in Drosophila (Figure 6). Together, these re-
sults also clearly show that mouse cells (Figures 3–5)
and embryos (Sva¨rd et al., 2006) lack a Cos2-like activity
that, in Drosophila, can completely suppress the Hh
pathway in the absence of Su(Fu). However, our results
should not be taken as evidence against novel proteins
(including kinesins not orthologous to Cos2) acting in
mammalian cells between Smo and GLI proteins with
mechanisms that are distinct from those used by Dro-
sophila Cos2. Several reports have, in fact, described
such vertebrate-specific regulators of Hh signaling,
including SIL (Izraeli et al., 2001), Iguana (Wolff et al.,
2004), Rab23 (Eggenschwiler et al., 2001), Kif3a, IFT88,
IFT172 (Huangfu and Anderson, 2005), MIM/BEG4
(Callahan et al., 2004), and b-arrestin2 (Wilbanks et al.,
2004).
Our results also shed light on some known differences
in the function of the Hh pathway in Drosophila and
mammals. Mutations and small molecules affecting
conformation of Smo transmembrane domains have
a strong effect in mammals (Taipale et al., 2000), but
they have little effect (Nakano et al., 2004; Taipale
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membrane domain is required for regulation of Su(Fu)
activity (Hooper, 2003), whereas the Smo C-terminal do-
main is critical for inhibition of Cos2 activity (Hooper,
2003; Jia et al., 2003). Thus, based on our data, manipu-
lations that affect the Smo transmembrane domain
would be predicted to affect Su(Fu) and therefore have
a limited role in Drosophila and a major effect in mam-
mals.
Divergence and Conservation at the Level of Smo
Although there are differences in mouse and Drosophila
Smo functional domains (Figures 1C and 3C), and a lack
of conservation of Smo phosphorylation sites (Figures 2
and 3C), conservation of Smo function at a level not in-
volving Cos2 is supported by the observation that muta-
tion of a conserved isoleucine (I573A in mSmo) results in
loss of both mouse (Figure 2) and Drosophila (Lum et al.,
2003b) Smo activity, yet does not result in a loss of Cos2
binding to dSmo (Figure 4A). In addition, dSmo proteins
that are activated by phosphomimetic mutations are
constitutively stabilized; yet, they are partially respon-
sive to Hh (Zhang et al., 2004), suggesting that, in addi-
tion to stabilization and phosphorylation, other, poten-
tially conserved mechanisms could be required to
generate fully active Smo in Drosophila as well.
In the mSmo C terminus, we identified six residues be-
tween amino acids 570 and 580 that resulted in signifi-
cant loss of mSmo activity. The predicted secondary
structure for this region is an a helix, in which these res-
idues would reside on the same side (Figure 2A), raising
the possibility that, together with the third Smo intracel-
lular loop, this region may form an interaction surface in-
volved in inactivation of Su(Fu) or activation of Ci/GLI.
Figure 6. Model of the Mechanistic Differences between Drosophila
and Mouse Hh Signal Transduction Pathways
Positive and negative components of the Hh pathway are shown in
green and red, respectively. In Drosophila (left), Ci transcriptional
activity is inhibited by association with two cytoplasmic complexes,
one containing Su(Fu), and the other containing Cos2 and Fu. In re-
sponse to Hh, dSmo is phosphorylated (P), stabilized, and binds to
the Cos2-Fu-Ci complex. The Cos2-containing complex is alone suf-
ficient to inhibit Ci activator formation, and Su(Fu) has a very minor
role (lighter color). In contrast, in the mouse (right), Cos2-like activity
does not affect GLI2 activator formation, whereas the Su(Fu) path-
way has a critical role. The dotted circle indicates the conserved re-
gion in mSmo that is required for transduction of the Hh signal to
Su(Fu) (see Figure 2). Despite the differential requirements of
Su(Fu) for Hh pathway function, the mechanism of Su(Fu) action ap-
pears to be conserved between Drosophila and mammals.Role of Su(Fu) in Cancer
Recent results have indicated that Su(Fu) acts as a tumor
suppressor in medulloblastoma (Taylor et al., 2002), and
it has been suggested that medulloblastomas associ-
ated with loss of Su(Fu) result, in part, from activation
of the Wnt pathway (Taylor et al., 2004). However, consis-
tent with the lack of a Wnt phenotype of Su(Fu) mutations
in Drosophila (DasGupta et al., 2005; Preat, 1992), in our
hands, a Wnt pathway-specific reporter (Lum et al.,
2003a) is not activated by shRNAs targeting Su(Fu)
(Figure S7; see also Sva¨rd et al. [2006]). Given our obser-
vations that Su(Fu) is critically important in the suppres-
sion of the mammalian Hh pathway in the absence of
ligand, and the fact that Hh pathway activation is re-
quired for growth of a form of medulloblastoma induced
by mutations in Patched (Berman et al., 2002), it is likely
that constitutive activation of the Hh pathway is also es-
sential for growth of medulloblastomas associated with
the loss of Su(Fu).
Evolution of Multicomponent Signaling Pathways
In a wider context, our results demonstrate that signal
transduction mechanisms of even the major signaling
pathways are not immutable, but that they can be sub-
ject to evolutionary change. The divergence may have
occurred after the separation of the vertebrate and in-
vertebrate lineages. However, some evidence also sug-
gests that functional divergence may have occurred
much later in evolution. Although mutants of Fused or
Cos2 orthologs of zebrafish have not been identified, re-
cently Wolff et al. (2003) and Tay et al. (2005) have re-
ported that zebrafish homologs of Fused and Cos2 act
in the Hh pathway based on morpholino antisense injec-
tions. In contrast to these findings, mice deficient in
mouse ortholog of Drosophila Fused do not have a Hh-
related phenotype (Chen et al., 2005; Merchant et al.,
2005), and mouse orthologs of Cos2 do not affect Hh
signaling (this report). Hh-related phenotypes can be
observed in zebrafish by morpholino-mediated target-
ing of other genes as well, such as b-arrestin2 (Wilbanks
et al., 2004), whose loss in mice does not result in
a Hh-related phenotype (Bohn et al., 1999). It is widely
appreciated that multiple types of embryonic insults re-
sult in Hh-like phenotypes, such as holoprosencephaly
(Muenke and Beachy, 2000). Thus, it is possible that
the zebrafish phenotypes observed are caused by the
morpholino injection process itself. Alternatively, there
may also be significant differences between the mecha-
nism of Hh signaling between vertebrate species (see
also Huangfu and Anderson, 2005; Sun et al., 2004).
Because of the strong conservation of Su(Fu) in both
invertebrate and vertebrate phyla, the presence of
a Cos2 binding domain only in insect Smo, and the diver-
gence of the Cos2 proteins from the kinesin family, the
simplest explanation of our data is that Su(Fu) repre-
sents the primordial Ci/GLI repressor, and that the
Cos2-like functionality has evolved specifically in the in-
vertebrate lineage. Our results, thus, also raise the pos-
sibility that multicomponent pathways evolve, in part, by
insertion of novel proteins between existing pathway
components. This mechanism potentially explains
a challenging aspect of evolutionary biology regarding
the emergence of signaling pathways with multiple spe-
cific components.
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Cell Culture
Drosophila cells were cultured in Drosophila-SFM (Invitrogen) with
10% fetal bovine serum at 23ºC. Mammalian cells were cultured in
DMEM containing 10% bovine calf serum (NIH-3T3, C3H10T1/2) or
fetal bovine serum (293-ShhN, COS1, s4Smo2/2) and antibiotics.
For generation of s4Smo2/2 cells, E8.5 mouse embryos homozygous
for the mSmo allele with loxP sites flanking exon1 were dissected to
pieces ofw0.5 mm diameter. The semidry pieces were allowed to ad-
here, and media were slowly added. After 4–7 days, fibroblastic cells
that had migrated from the embryos were collected by trypsinization.
The cells were cultured through crisis, and s4Smo2/2 cells lacking
mSmo exon1 were generated by cotransfection of CRE and the hy-
gromycin resistance vector, followed by hygromycin selection.
Loss of Smo exon1 was confirmed by genotyping with the following
primers: 50-GGTTCCCAGGGTTGAAGACA-30 and 50-CCCCTCGACT
CCCAACTTT-30. Stable lines expressing triple-myc-tagged mSmo
were generated by transfecting another (non-hygromycin-resistant)
embryonic fibroblast cell line from mSmo-targeted mice lacking
mSmo expression with pcDNA3.1-Hygro-mSmomyc3 vector, fol-
lowed by selection.
Constructs, Transfections, and RNAi Analyses
cDNA and shRNA constructs are described in the Supplemental Ex-
perimental Procedures. Drosophila cells were transfected with Ef-
fectene (Qiagen), and reporter assays were performed after 2 days
as described in Lum et al. (2003a). Mammalian reporter assays
were performed essentially as described in Taipale et al. (2002).
Briefly, after transfection with Fugene6 (2 days), cell culture medium
was changed to DMEM with 0.5% bovine calf serum with or without
ShhN (from 293-ShhN cell-conditioned medium [Chen et al., 2002b],
1:10 v/v). Relative luciferase activity (ratio of firefly luciferase to Re-
nilla luciferase) was measured after 2–3 days. Using Fugene6, the
transfection efficiency wasw1%–5%, and each transfected cell re-
ceived >> 100 plasmids on average, as indicated by the ability of 1%
w/w of mSmo DNA to completely rescue the loss of mSmo (Fig-
ure 1A; see also [Taipale et al., 2002]). At 1%–3% w/w DNA, the ex-
pression level and distribution of mSmo was similar to that of endog-
enous mSmo (Figure S1D).
Antibodies and Immunochemistry
Antibodies used were: polyclonal rabbit-anti Smo (Lifespan Biosci-
ences A2666), monoclonal anti-V5 epitope tag (Invitrogen 46-0705),
mono- and polyclonal anti-myc-epitope (Santa Cruz Biotechnology
9E10, A14), and Alexa594-conjugated anti-mouse and anti-rabbit
(Molecular Probes). The immunoprecipitation protocol is described
in the Supplemental Experimental Procedures. A GF-cyclopamine
binding assay was performed according to Chen et al. (2002a). For
immunofluorescence, NIH-3T3 cells were seeded on fibronectin-
coated coverslips (BD Biosciences) and were transfected with the
constructs indicated. After 2 days, the coverslips were washed, fixed
with 4% PFA, permeabilized, stained, and mounted for observation
with a Zeiss AxioplanII microscope (for GFP, a Chroma 31026 narrow
band filter was used). Nuclear localization was confirmed by DAPI
staining.
Northern Blotting
Mouse embryo (7763-1) and mouse multiple tissue (7762-1) Northern
blots were purchashed from Clontech. Probes for Kif27 (base pairs
3148–4185) and Kif7 (3064–3987) were labeled with the Rediprime
DNA labeling kit (Amersham), and hybridizations were performed
in HybriMax solution (Ambion). The filter was washed under strin-
gent conditions (0.1% SSC, 1% SDS at 65ºC) and was subjected
to autoradiography on Kodak BioMax MS film.
Supplemental Data
Supplemental Data including seven figures and Supplemental Exper-
imental Procedures are available at http://www.developmentalcell.
com/cgi/content/full/10/2/177/DC1/.
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